ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Junshi Allies With Rxilient On JV
ScripUK microbiome-based drug developer 4D Pharma has become the latest NASDAQ-listed biotech company to go into administration, after a creditor called time on its debts. The Leeds-based company suspend
ScripBiotechs developing microbiome modulators are benefitting from improved investor sentiment as strong clinical outcomes de-risk investment and one key player, Microbiotica Ltd. , has just raised an im
ScripUsing the microbiome in the context of oncology is a relatively new concept, but Osel, Inc. is already looking to move its product candidate into Phase III on the back of data from a kidney cancer s